EQT Life Sciences participates in RQ Bio’s USD 115 million Series A financing
· EQT Life Sciences joins new investors Frazier Life Sciences, Forbion, Monograph and Wellington Management, alongside existing investors LifeArc, Oxford Science Enterprises and Oxford University Innovation, in RQ Bio’s oversubscribed USD 115 million Series A financing · RQ Bio is developing antibody therapies to prevent seasonal influenza in high-risk and immunocompromised populations, with the Series A supporting its clinical progression and broader infectious disease pipeline · As part of the financing, RQ Bio appointed Christian S. Schade as Executive Chairman, having most recently